Trial Profile

A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERAPY-BASED TREATMENT

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions; Registrational
Acronyms KAMILLA
Sponsors Roche

08 Jun 2021 Final results from KAMILLA Cohorts 1 (global) and 2 (Asia) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
09 Sep 2020 Status changed from active, no longer recruiting to completed.
04 Jul 2020 Results (n=2003) of exploratory final analysis of cohort 1 from KAMILLA published in the Annals of Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com